Purpose

After glioblastoma (GB) recurrence, prognosis is very cumbersome. Therefore, health-related quality of life (HRQoL) and neurocognitive functioning (NCF) have become important endpoints in clinical trials when evaluating novel treatments. We aimed to evaluate the HRQoL and NCF in patients with recurrent glioblastoma (rGB) treated with a combination of surgical intervention (reoperation or biopsy) and intracerebral immune checkpoint inhibition.

Methods

Patients who participated in the trial (N = 23), at a single-center university hospital were included. Data were collected using 3 patient-reported outcome measures (EORTC-QLQ-C30, EORTC-QLQ-BN20, and HADS) and computerized NCF testing. In the responder group, baseline values were compared to results at a 6-month follow-up. Additionally, exploratory analyses compared baseline HRQoL and NCF between responders and non-responders.

Results

There were five responders and 18 non-responders. When comparing the mean and individual baseline with follow-up results for the responders, we observed overall a stable to slight clinically relevant improvement of HRQoL in multiple subsets of the questionnaires while maintaining a stable NCF. One patient deteriorated on anxiety and depression symptoms from baseline to follow-up.

Conclusions

In patients that responded to intracerebral immunotherapy in our institutional trial, HRQoL and NCF remained stable over time, suggesting that no detrimental effect on cognitive function or quality of life may be expected with this treatment approach. Furthermore, there seems to be an overall tendency for responders to score better on HRQoL and NCF than non-responders at baseline.

中文翻译：

---

接受脑内免疫检查点抑制治疗的复发性胶质母细胞瘤患者的健康相关生活质量和神经认知功能

目的

胶质母细胞瘤（GB）复发后，预后非常麻烦。因此，在评估新疗法时，健康相关的生活质量（HRQoL）和神经认知功能（NCF）已成为临床试验的重要终点。我们的目的是评估结合手术干预（再次手术或活检）和脑内免疫检查点抑制治疗的复发性胶质母细胞瘤（rGB）患者的 HRQoL 和 NCF。

方法

 参加单中心大学医院试验的患者 ( N = 23) 被纳入其中。使用 3 种患者报告的结果测量（EORTC-QLQ-C30、EORTC-QLQ-BN20 和 HADS）和计算机化 NCF 测试收集数据。在应答组中，将基线值与 6 个月随访的结果进行比较。此外，探索性分析还比较了应答者和非应答者之间的基线 HRQoL 和 NCF。

结果

有 5 名回应者和 18 名未回应者。当将平均基线和个体基线与应答者的随访结果进行比较时，我们观察到，在维持稳定的 NCF 的同时，多个问卷子集中的 HRQoL 总体上有稳定至轻微的临床相关改善。从基线到随访，一名患者的焦虑和抑郁症状恶化。

结论

在我们的机构试验中对脑内免疫治疗有反应的患者中，HRQoL 和 NCF 随着时间的推移保持稳定，这表明这种治疗方法预计不会对认知功能或生活质量产生不利影响。此外，总体趋势似乎是，基线时响应者在 HRQoL 和 NCF 上的得分高于无响应者。